Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dinaciclib - Merck & Co

Drug Profile

Dinaciclib - Merck & Co

Alternative Names: MK-7965; PS-095760; SCH 727965; SCHOOL 727965

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacopeia
  • Developer AbbVie; Baylor College of Medicine; Merck & Co; University of California at San Francisco
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase I Acute myeloid leukaemia; Breast cancer
  • Preclinical Hepatoblastoma
  • No development reported Non-small cell lung cancer
  • Discontinued Leukaemia; Mantle-cell lymphoma

Most Recent Events

  • 10 Dec 2022 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 01 Dec 2022 AbbVie in collaboration with Merck Sharp & Dohme terminates phase Ib trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Spain, Australia and US (IV), due to strategic considerations (NCT03484520)
  • 29 Sep 2022 Dinaciclib is still in phase I trials for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, In adults, In the elderly) in USA (IV) (NCT01676753)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top